The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 6, Issue 1, 2010, Pages 170-178

  Yan, Fei ^a   Zhang, Chao ^b   Zheng, Yi ^a   Mei, Lin ^a,b,c   Tang, Lina ^b   Song, Cunxian ^b   Sun, Hongfan ^b   Huang, Laiqiang ^a  

^a Center for Biotech and Bio Medicine   (China)

^b INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cell viability; Docetaxel; Nanoparticles; Poloxamer 188

Indexed keywords

BLOCK COPOLYMERS; CELL CULTURE; CELLS; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; DISEASES; DRUG PRODUCTS; EMULSIFICATION; EMULSIONS; MORPHOLOGY; TARGETED DRUG DELIVERY;

BREAST CANCER; CELL VIABILITY; DOCETAXEL; HUMAN BREAST CANCER CELLS; NANOPARTICLE FORMULATION; NARROW SIZE DISTRIBUTIONS; POLOXAMER; POLY(LACTIC-CO-GLYCOLIC ACID);

NANOPARTICLES;

DOCETAXEL; NANOPARTICLE; POLOXAMER; POLYGLACTIN; WATER OIL CREAM;

ARTICLE; BREAST CANCER; CANCER CELL; CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; EMULSION; EVAPORATION; HUMAN; HUMAN CELL; NANOENCAPSULATION; NANOPHARMACEUTICS; PARTICLE SIZE;

EID: 75449093784     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2009.05.004     Document Type: Article

References (34)

1. Tanaka T., Decuzzi P., Cristofanilli M., Sakamoto J.H., Tasciotti E., Robertson F.M., and Ferrari M. Nanotechnology for breast cancer therapy. Biomed Microdevices 11 (2008) 49-63
2. Direcks W.G.E., Berndsen S.C., Proost N., Peters G.J., Balzarini J., Spreeuwenberg M.D., et al. [18F] FDG and [18F] FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer 99 (2008) 481-487
3. Gottesman M.M. How cancer cells evade chemotherapy. Cancer Res 53 (1993) 747-754
4. Gelperina S., Kisich K., Iseman M.D., and Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172 (2005) 1487-1490
5. Li C. Poly(L-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev 54 (2002) 695-713
6. Davda J., and Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 233 (2002) 51-59
7. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54 (2002) 631-651
8. Khayat D., Antoine E.C., and Coeffic D. Taxol in the management of cancers of the breast and the ovary. Cancer Invest 18 (2000) 242-260
9. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22 (2003) 9075-9086
10. Hernandez-Vargas H., Palacios J., and Moreno-Bueno G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of abberrant mitosis and apoptosis. Oncogene 26 (2007) 2902-2913
11. Immordino M.L., Brusa P., Arpicco S., Stella B., Dosio F., and Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Controlled Release 91 (2003) 417-429
12. Engels F.K., Mathot R.A., and Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 8 (2007) 95-103
13. Baker S.D., Zhao M., He P., Carducci M.A., Verweij J., and Sparreboom A. Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem 324 (2004) 276-284
14. Collins D. Docetaxel uptake and modulation of P-gp mediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines. PhD thesis, Dublin City University, 2008.
15. Jain R.A., Rhodes C.T., Railkar A.M., Malick A.W., and Shah N.H. Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables. Eur J Pharm Biopharm 50 (2000) 257-262
16. Duvvuri S., Janoria K.G., and Mitra A.K. Development of a novel formulation containing poly(D,L-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J Controlled Release 108 (2005) 282-293
17. Moghimi S.M., and Hunter A.C. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol 18 (2000) 412-420
18. Santander-Ortega M.J., Jódar-Reyes A.B., Csaba N., Bastos-González D., and Ortega-Vinuesa J.L. Colloidal stability of pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms. J Colloid Interface Sci 302 (2006) 522-529
19. Mei L., Sun H., Jin X., Zhu D., Sun R., Zhang M., and Song C. Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm Res 24 (2007) 955-962
20. Reich G. In vitro stability of poly(D,L-lactide) and poly(D,L-lactide)/poloxamer nanoparticles in gastrointestinal fluids. Drug Dev Ind Pharm 23 (1997) 1191-1198
21. Fontana G., Pitarresi G., Tomarchio V., Carlisi B., and San Biagio P.L. Preparation, characterization and in vitro antimicrobial activity of ampicillin-loaded polyethylcyanoacrylate nanoparticles. Biomaterials 19 (1998) 1009-1017
22. Sun H., Mei L., Song C., Cui X., and Wang P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials 27 (2006) 1735-1740
23. Storm G., Belliot S.O., Daemen T., and Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 16 (1995) 31-48
24. Li J.T., Caldwell K.D., and Rapoport N. Surface properties of pluronic-coated polymeric colloids. Langmuir 10 (1994) 4475-4482
25. Gref R., Domb A., Quellec P., Blunk T., Muller R.H., Verbavatz J.M., and Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 16 (1995) 215-233
26. Ma G.L., and Song C.X. PCL/poloxamer 188 blend microsphere for paclitaxel delivery: influence of poloxamer 188 on morphology and drug release. J Appl Polym Sci 104 (2007) 1895-1899
27. Qaddoumi M.G., Ueda H., Yang J., Davda J., Labhasetwar V., and Lee V.H.L. The characteristic and mechanisms of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res 21 (2004) 641-648
28. Desai M.P., Labhasetwar V., Walter E., Levy R.J., and Amidon G.L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 14 (1997) 1568-1573
29. Rejman J., Oberle V., Zuhorn I.S., and Hoekstra D. Size-dependent internalization of particle via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 377 (2004) 159-169
30. Batrakova E.V., and Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Controlled Release 130 (2008) 98-106
31. Yang Z., Sahay G., Sriadibhatla S., and Kabanov A.V. Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA. Bioconjug Chem 19 (2008) 1987-1994
32. Huang J., Si L., Jiang L., Fan Z., Qiu J., and Li G. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int J Pharm 356 (2008) 351-353
33. Pal D., and Mitra A.K. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 78 (2006) 2131-2145
34. Kabanov A.V., Batrakova E.V., and Alakhov V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 54 (2002) 759-779